PhaseRx, Inc. Stock

PZRXQ

US71723F1030

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 13:31:34 2025-12-10 EST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

19-01-30	Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc.	CI
18-03-23	PhaseRx, Inc. Bankruptcy Case Dismissed	CI

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The Company's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
PZRXQ Stock

As early as today, start finding the best investment opportunities!

Market Cap	4.56M 3.96M 3.69M 3.39M 6.4M 435M 6.5M 43.48M 17.07M 217M 17.12M 16.75M 727M	P/E 2015 *	-	P/E 2016	-0.58x
Enterprise Value	-5.22M -4.53M -4.22M -3.88M -7.32M -498M -7.43M -49.76M -19.53M -248M -19.59M -19.16M -831M	EV / Sales 2015 *	-	EV / Sales 2016	-
Free-Float	100%	Yield 2015 *	-	Yield 2016	-

19-01-30	Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc.	CI
18-03-23	PhaseRx, Inc. Bankruptcy Case Dismissed	CI
18-03-06	Motion for Case Dismissal Filed for PhaseRx, Inc.	CI
18-02-20	Motion for De Minimis Asset Sale Approved for PhaseRx, Inc.	CI
18-02-02	PhaseRx, Inc.(OTCPK:PZRX.Q) dropped from NASDAQ Composite Index	CI
18-02-01	Motion for Asset Sale Approved for PhaseRx, Inc.	CI
18-01-31	Roivant Sciences GmbH entered into an asset purchase agreement to acquire substantially all of the assets from PhaseRx, Inc. for $6.8 million.	CI
17-12-27	Bidding Procedure Approved for PhaseRx, Inc.	CI
17-12-14	PhaseRx Considers Multiple Alternatives	CI
17-12-13	PhaseRx, Inc.(NasdaqCM:PZRX) dropped from S&P TMI Index	CI
17-12-11	PhaseRx, Inc. Filed for Bankruptcy	CI
17-12-11	Motion for Asset Sale Filed by PhaseRx, Inc.	CI
17-11-09	PhaseRx, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	CI

1 year	0		0
3 years	0		0
5 years	0		0.03
10 years	0		3.98

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHASERX, INC.	-.--%	-.--%	-	-	11
WUXI APPTEC CO., LTD.	+2.35%	+2.74%	+38.10%	+71.29%	56.54B
ARGENX SE	-0.21%	-7.38%	+27.52%	+61.15%	53.6B
BIONTECH SE	-2.44%	+1.40%	-15.61%	-15.45%	22.91B
INSMED INCORPORATED	-2.85%	-7.78%	-9.28%	+345.55%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+2.49%	-0.92%	+23.57%	-13.14%	20.27B
GENMAB A/S	+0.79%	-1.06%	+33.99%	-31.95%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.58%	-5.88%	+19.40%	+527.50%	14.75B
PHARMAESSENTIA CORPORATION	+3.41%	-6.61%	+162.81%	+278.22%	13.53B
EXELIXIS, INC.	-5.25%	-4.23%	+42.32%	+170.15%	13.33B
Average	-0.11%	-3.41%	+35.87%	+154.81%	23.39B
Weighted average by Cap.	+0.23%	-2.96%	+30.79%	+116.84%

	2015	2016
Net sales	375K 326K 303K 279K 526K 35.8M 534K 3.58M 1.4M 17.82M 1.41M 1.38M 59.76M	-
Net income	-7.38M -6.41M -5.97M -5.48M -10.35M -704M -10.51M -70.36M -27.61M -351M -27.71M -27.1M -1.18B	-20.14M -17.51M -16.29M -14.96M -28.25M -1.92B -28.69M -192M -75.38M -957M -75.63M -73.97M -3.21B
Net Debt	16.55M 14.39M 13.39M 12.3M 23.22M 1.58B 23.58M 158M 61.95M 787M 62.16M 60.79M 2.64B	-9.78M -8.5M -7.91M -7.26M -13.71M -933M -13.93M -93.24M -36.59M -465M -36.71M -35.91M -1.56B

PhaseRx, Inc. Stock

Stocks

PZRXQ

US71723F1030

Biotechnology & Medical Research

Valuation: PhaseRx, Inc.

Chart: PhaseRx, Inc.

Latest news : PhaseRx, Inc.

Course Extremes

Bio Therapeutic Drugs

Financials

Company Profile